A Look at Johnson & Johnson’s Valuation Following Back-to-Back FDA Approvals for Oncology and Neuropsychiatry Therapies

Johnson & Johnson (JNJ) just secured back-to-back FDA approvals for two therapies, representing a meaningful expansion in both its oncology and neuropsychiatry portfolios. These developments could open up additional opportunities for long-term growth. See our latest analysis for Johnson & Johnson. These approvals have come amid a stretch of strong momentum for Johnson & Johnson, with the stock delivering a robust 9.05% share price gain over the last quarter and an impressive 25.45% total...